Genetic/Familial High-Risk Assessment: Breast and Ovarian Clinical Practice Guidelines in Oncology
NCCN Categories of Evidence and Consensus
Category 1: The recommendation is based on high-level evidence (e.g., randomized controlled trials) and there is uniform NCCN consensus.
Category 2A: The recommendation is based on lower-level evidence and there is uniform NCCN consensus.
Category 2B: The recommendation is based on lower-level evidence and there is nonuniform NCCN consensus (but no major disagreement).
Category 3: The recommendation is based on any level of evidence but reflects major disagreement.
All recommendations are category 2A unless otherwise noted.
Clinical trials: The NCCN believes that the best management for any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
These guidelines are a statement of consensus of the authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these guidelines is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient's care or treatment. The National Comprehensive Cancer Network makes no representation or warranties of any kind regarding their content, use, or application and disclaims any responsibility for their applications or use in any way.
These guidelines are copyrighted by the National Comprehensive Cancer Network. All rights reserved. These guidelines and the illustrations herein may not be reproduced in any form without the express written permission of the NCCN © 2010.
Disclosures for the NCCN Genetic/Familial High-Risk Assessment: Breast and Ovarian Guidelines Panel
At the beginning of each NCCN guidelines panel meeting, panel members disclosed any financial support they have received from industry. Through 2008, this information was published in an aggregate statement in JNCCN and online. Furthering NCCN's commitment to public transparency, this disclosure process has now been expanded by listing all potential conflicts of interest respective to each individual expert panel member.
Individual disclosures for the NCCN Genetic/Familial High-Risk Assessment: Breast and Ovarian Guidelines Panel members can be found on page 594. (The most recent version of these guidelines and accompanying disclosures, including levels of compensation, are available on the NCCN Web site at www.NCCN.org.)
These guidelines are also available on the Internet. For the latest update, please visit www.NCCN.org.
NCCN Genetic/Familial High-Risk Assessment: Breast and Ovarian Panel Members
*Mary B. Daly, MD, PhD/Chair†
Fox Chase Cancer Center
Jennifer E. Axilbund, MS, CGCΔ
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Saundra Buys, MD†þ‡
Huntsman Cancer Institute at the University of Utah
Beth Crawford, MS, CGCΔ
UCSF Helen Diller Family Comprehensive Cancer Center
Carolyn D. Farrell, MS, CNP, CGCΔ
Roswell Park Cancer Institute
Susan Friedman, DVM¥
FORCE-Facing Our Risk of Cancer Empowered
Judy E. Garber, MD, MPH†
Dana-Farber/Brigham and Women's Cancer Center
Salil Goorha, MD†
St. Jude Children's Research Hospital/University of Tennessee Cancer Institute
Stephen B. Gruber, MD, PhD, MPHΔ
University of Michigan Comprehensive Cancer Center
Heather Hampel, MS, CGCΔ
The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute
Virginia Kaklamani, MD‡
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
*Wendy Kohlmann, MS, CGCΔ
Huntsman Cancer Institute at the University of Utah
Allison Kurian, MD, MSc†þΔ
Stanford Comprehensive Cancer Center
Jennifer Litton, MD†
The University of Texas M. D. Anderson Cancer Center
P. Kelly Marcom, MD†
Duke Comprehensive Cancer Center
Robert Nussbaum, MDþΔ
UCSF Helen Diller Family Comprehensive Cancer Center
Kenneth Offit, MD†þΔ
Memorial Sloan-Kettering Cancer Center
Tuya Pal, MDΔ
H. Lee Moffitt Cancer Center & Research Institute
Boris Pasche, MD, PhD‡þΔ
University of Alabama at Birmingham Comprehensive Cancer Center
*Robert Pilarski, MS, CGCΔ
The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute
Gwen Reiser, MS, CGCΔ
UNMC Eppley Cancer Center at The Nebraska Medical Center
Kristen Mahoney Shannon, MS, CGCΔ
Massachusetts General Hospital Cancer Center
Jeffrey R. Smith, MD, PhDΔ
Vanderbilt-Ingram Cancer Center
Elizabeth Swisher, MD
University of Washington/Seattle Cancer Care Alliance
Jeffrey N. Weitzel, MD†‡Δ
City of Hope Comprehensive Cancer Center
*Writing Committee Member
Specialties: †Medical Oncology; ΔCancer Genetics; þInternal Medicine; ‡Hematology/Hematology Oncology; ¥Patient Advocacy
PharoahPDDayNEDuffyS. Family history and the risk of breast cancer: a systematic review and meta-analysis. Int J Cancer1997;71:800–809.
BerlinerJLFayAM. Risk assessment and genetic counseling for hereditary breast and ovarian cancer: recommendations of the National Society of Genetic Counselors. J Genet Couns2007;16:241–260.
TrepanierAAhrensMMcKinnonW. Genetic cancer risk assessment and counseling: recommendations of the national society of genetic counselors. J Genet Couns2004;13:83–114.
SchneiderKAGarberJ. (Updated February 9 2010)Li-Fraumeni syndrome. InGeneReviews at GeneTests: Medical Genetics Information Resource (database online); CopyrightUniversity of WashingtonSeattle. 1997–2010. Available at: http://www.genetests.org. Accessed March 3 2010.
Brooks-WilsonARKaurahPSurianoG. Germline E-cadherin mutations in hereditary diffuse gastric cancer: assessment of 42 new families and review of genetic screening criteria. J Med Genet2004;41:508–517.
KaurahPMacMillanABoydN. Founder and recurrent CDH1 mutations in families with hereditary diffuse gastric cancer. JAMA2007;297:2360–2372.
OliveiraCBordinMCGrehanN. Screening E-cadherin in gastric cancer families reveals germline mutations only in hereditary diffuse gastric cancer kindred. Hum Mutat2002;19:510–517.
SimonRZhangX. On the dynamics of breast tumor development in women carrying germline BRCA1 and BRCA2 mutations. Int J Cancer2008;122:1916–1917.
BergmanAEinbeigiZOlofssonU. The western Swedish BRCA1 founder mutation 3171ins5; a 3.7 cM conserved haplotype of today is a reminiscence of a 1500-year-old mutation. Eur J Hum Genet2001;9:787–793.
CsokayBUdvarhelyiNSulyokZ. High frequency of germline BRCA2 mutations among Hungarian male breast cancer patients without family history. Cancer Res1999;59:995–998.
MikaelsdottirEKValgeirsdottirSEyfjordJERafnarT. The Icelandic founder mutation BRCA2 999del5: analysis of expression. Breast Cancer Res2004;6:R284–290.
Petrij-BoschAPeelenTvan VlietM. BRCA1 genomic deletions are major founder mutations in Dutch breast cancer patients. Nat Genet1997;17:341–345.
ToninPNMes-MassonAMFutrealPA. Founder BRCA1 and BRCA2 mutations in French Canadian breast and ovarian cancer families. Am J Hum Genet1998;63:1341–1351.
FordDEastonDFStrattonM. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet1998;62:676–689.
CipakLWatanabeNBesshoT. The role of BRCA2 in replication-coupled DNA interstrand cross-link repair in vitro. Nat Struct Mol Biol2006;13:729–733.
WoosterRNeuhausenSLMangionJ. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13Science1994;265:2088–2090.
AbeliovichDKaduriLLererI. The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women. Am J Hum Genet1997;60:505–514.
Levy-LahadECataneREisenbergS. Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel: frequency and differential penetrance in ovarian cancer and in breast-ovarian cancer families. Am J Hum Genet1997;60:1059–1067.
PetrucelliNDalyMBBars CulverJOFeldmanGL. (Updated June 19 2007). BRCA1 and BRCA2 hereditary breast/ovarian cancer. InGeneReviews at GeneTests: Medical Genetics Information Resource (database online); CopyrightUniversity of WashingtonSeattle. 1997–2010. Available at: http://www.genetests.org. Accessed March 3 2010.
AntoniouAPharoahPDNarodS. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet2003;72:1117–1130.
FinchABeinerMLubinskiJ. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation. JAMA2006;296:185–192.
RischHAMcLaughlinJRColeDE. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet2001;68:700–710.
AtchleyDPAlbarracinCTLopezA. Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. J Clin Oncol2008;26:4282–4288.
LakhaniSRReis-FilhoJSFulfordL. Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res2005;11:5175–5180.
LakhaniSRVan De VijverMJJacquemierJ. The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol2002;20:2310–2318.
YoungSRPilarskiRTDonenbergT. The prevalence of BRCA1 mutations among young women with triple-negative breast cancer. BMC Cancer2009;9:86.
LiedeAKarlanBYNarodSA. Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature. J Clin Oncol2004;22:735–742.
Lorenzo BermejoJHemminkiK. Risk of cancer at sites other than the breast in Swedish families eligible for BRCA1 or BRCA2 mutation testing. Ann Oncol2004;15:1834–1841.
BeinerMEFinchARosenB. The risk of endometrial cancer in women with BRCA1 and BRCA2 mutations. A prospective study. Gynecol Oncol2007;104:7–10.
JazaeriAALuKSchmandtR. Molecular determinants of tumor differentiation in papillary serous ovarian carcinoma. Mol Carcinog2003;36:53–59.
BjorgeTLieAKHovigE. BRCA1 mutations in ovarian cancer and borderline tumours in Norway: a nested case-control study. Br J Cancer2004;91:1829–1834.
PressJZDe LucaABoydN. Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities. BMC Cancer2008;8:17.
PalTPermuth-WeyJBettsJA. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer2005;104:2807–2816.
RischHAMcLaughlinJRColeDE. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. J Natl Cancer Inst2006;98:1694–1706.
GaytherSARussellPHarringtonP. The contribution of germline BRCA1 and BRCA2 mutations to familial ovarian cancer: no evidence for other ovarian cancer-susceptibility genes. Am J Hum Genet1999;65:1021–1029.
SekineMNagataHTsujiS. Localization of a novel susceptibility gene for familial ovarian cancer to chromosome 3p22-p25. Hum Mol Genet2001;10:1421–1429.
LynchHTCaseyMJSnyderCL. Hereditary ovarian carcinoma: heterogeneity, molecular genetics, pathology, and management. Mol Oncol2009;3:97–137.
KauffNDMitraNRobsonME. Risk of ovarian cancer in BRCA1 and BRCA2 mutation-negative hereditary breast cancer families. J Natl Cancer Inst2005;97:1382–1384.
CouchFJFaridLMDeShanoML. BRCA2 germline mutations in male breast cancer cases and breast cancer families. Nat Genet1996;13:123–125.
FriedmanLSGaytherSAKurosakiT. Mutation analysis of BRCA1 and BRCA2 in a male breast cancer population. Am J Hum Genet1997;60:313–319.
American Chemical Society. What are the key statistics about breast cancer in men?Available at: http://www.cancer.org/docroot/CRI/content/CRI_2_4_1X_What_are_the_key_statistics_for_male_breast_cancer_28.asp. Accessed on March 3 2010.
GonzalezKDNoltnerKABuzinCH. Beyond Li Fraumeni syndrome: clinical characteristics of families with p53 germline mutations. J Clin Oncol2009;27:1250–1256.
NicholsKEMalkinDGarberJE. Germ-line p53 mutations predispose to a wide spectrum of early-onset cancers. Cancer Epidemiol Biomarkers Prev2001;10:83–87.
SiddiquiROnelKFacioF. The TP53 mutational spectrum and frequency of CHEK2*1100delC in Li-Fraumeni-like kindreds. Fam Cancer2005;4:177–181.
BirchJMHartleyALTrickerKJ. Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li-Fraumeni families. Cancer Res1994;54:1298–1304.
KrutilkovaVTrkovaMFleitzJ. Identification of five new families strengthens the link between childhood choroid plexus carcinoma and germline TP53 mutations. Eur J Cancer2005;41:1597–1603.
MalkinDLiFPStrongLC. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science1990;250:1233–1238.
LustbaderEDWilliamsWRBondyML. Segregation analysis of cancer in families of childhood soft-tissue-sarcoma patients. Am J Hum Genet1992;51:344–356.
ChompretAAbelAStoppa-LyonnetD. Sensitivity and predictive value of criteria for p53 germline mutation screening. J Med Genet2001;38:43–47.
BirchJMBlairVKelseyAM. Cancer phenotype correlates with constitutional TP53 genotype in families with the Li-Fraumeni syndrome. Oncogene1998;17:1061–1068.
BougeardGSesboueRBaert-DesurmontS. Molecular basis of the Li-Fraumeni syndrome: an update from the French LFS families. J Med Genet2008;45:535–538.
GinsburgOMAkbariMRAzizZ. The prevalence of germline TP53 mutations in women diagnosed with breast cancer before age 30. Fam Cancer2009;8:563–567.
NelenMRKremerHKoningsIB. Novel PTEN mutations in patients with Cowden disease: absence of clear genotype-phenotype correlations. Eur J Hum Genet1999;7:267–273.
PilarskiREngC. Will the real Cowden syndrome please stand up (again)? Expanding mutational and clinical spectra of the PTEN hamartoma tumour syndrome. J Med Genet2004;41:323–326.
EngC. PTEN hamartoma tumor syndrome (PTHS). GeneReviews Web site. Available at: http://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=gene&part=phts#phts. Accessed March 3 2010.
SchafferJVKaminoHWitkiewiczA. Mucocutaneous neuromas: an underrecognized manifestation of PTEN hamartoma-tumor syndrome. Arch Dermatol2006;142:625–632.
Al-ThihliKPalmaLMarcusV. A case of Cowden's syndrome presenting with gastric carcinomas and gastrointestinal polyposis. Nat Clin Pract Gastroenterol Hepatol2009;6:184–189.
ZhouXPWaiteKAPilarskiR. Germline PTEN promoter mutations and deletions in Cowden/Bannayan-Riley-Ruvalcaba syndrome result in aberrant PTEN protein and dysregulation of the phosphoinositol-3-kinase/Akt pathway. Am J Hum Genet2003;73:404–411.
AndresRHGuzmanRWeisJ. Lhermitte-Duclos disease with atypical vascularization—case report and review of the literature. Clin Neuropathol2009;28:83–90.
ButlerMGDasoukiMJZhouXP. Subset of individuals with autism spectrum disorders and extreme macrocephaly associated with germline PTEN tumour suppressor gene mutations. J Med Genet2005;42:318–321.
HermanGEButterEEnrileB. Increasing knowledge of PTEN germline mutations: Two additional patients with autism and macrocephaly. Am J Med Genet2007;143:589–593.
VargaEAPastoreMPriorT. The prevalence of PTEN mutations in a clinical pediatric cohort with autism spectrum disorders, developmental delay, and macrocephaly. Genet Med2009;11:111–117.
MarshDJCoulonVLunettaKL. Mutation spectrum and genotype-phenotype analyses in Cowden disease and Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN mutation. Hum Mol Genet1998;7:507–515.
MurffHJSpigelDRSyngalS. Does this patient have a family history of cancer? An evidence-based analysis of the accuracy of family cancer history. JAMA2004;292:1480–1489.
ColditzGAWillettWCHunterDJ. Family history, age, and risk of breast cancer. Prospective data from the Nurses' Health Study. JAMA1993;270:338–343.
SlatteryMLKerberRA. A comprehensive evaluation of family history and breast cancer risk. The Utah Population Database. JAMA1993;270:1563–1568.
ClausEBRischNThompsonWD. Autosomal dominant inheritance of early-onset breast cancer. Implications for risk prediction. Cancer1994;73:643–651.
AntoniouACHardyRWalkerL. Predicting the likelihood of carrying a BRCA1 or BRCA2 mutation: validation of BOADICEA, BRCAPRO, IBIS, Myriad and the Manchester scoring system using data from UK genetics clinics. J Med Genet2008;45:425–431.
SaslowDBoetesCBurkeW. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin2007;57:75–89.
BlumanLGRimerBKBerryDA. Attitudes, knowledge, and risk perceptions of women with breast and/or ovarian cancer considering testing for BRCA1 and BRCA2. J Clin Oncol1999;17:1040–1046.
BennettRLFrenchKSRestaRGDoyleDL. Standardized human pedigree nomenclature: update and assessment of the recommendations of the National Society of Genetic Counselors. J Genet Couns2008;17:424–433.
BennettRLSteinhausKAUhrichSB. Recommendations for standardized human pedigree nomenclature. Pedigree Standardization Task Force of the National Society of Genetic Counselors. Am J Hum Genet1995;56:745–752.
WeitzelJNLagosVICullinaneCA. Limited family structure and BRCA gene mutation status in single cases of breast cancer. JAMA2007;297:2587–2595.
BodianCAPerzinKHLattesR. Lobular neoplasia. Long term risk of breast cancer and relation to other factors. Cancer1996;78:1024–1034.
OsborneMPHodaSA. Current management of lobular carcinoma in situ of the breast. Oncology (Williston Park)1994;8:45–49; discussion 49 53–44.
BeralVDollRHermonC. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet2008;371:303–314.
ChlebowskiRTHendrixSLLangerRD. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA2003;289:3243–3253.
RossouwJEAndersonGLPrenticeRL. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA2002;288:321–333.
WeissLKBurkmanRTCushing-HaugenKL. Hormone replacement therapy regimens and breast cancer risk(1). Obstet Gynecol2002;100:1148–1158.
American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility. J Clin Oncol2003;21:2397–2406.
RobsonMEStormCDWeitzelJ. American society of clinical oncology policy statement update: genetic and genomic testing for cancer susceptibility. J Clin Oncol2010;28:893–901.
BougeardGBaert-DesurmontSTournierI. Impact of the MDM2 SNP309 and p53 Arg72Pro polymorphism on age of tumour onset in Li-Fraumeni syndrome. J Med Genet2006;43:531–533.
ChibonFPrimoisCBressieuxJM. Contribution of PTEN large rearrangements in Cowden disease: a multiplex amplifiable probe hybridisation (MAPH) screening approach. J Med Genet2008;45:657–665.
PalmaMDDomchekSMStopferJ. The relative contribution of point mutations and genomic rearrangements in BRCA1 and BRCA2 in high-risk breast cancer families. Cancer Res2008;68:7006–7014.
WeitzelJNLagosVIHerzogJS. Evidence for common ancestral origin of a recurring BRCA1 genomic rearrangement identified in high-risk Hispanic families. Cancer Epidemiol Biomarkers Prev2007;16:1615–1620.
OffitKLevranOMullaneyB. Shared genetic susceptibility to breast cancer, brain tumors, and Fanconi anemia. J Natl Cancer Inst2003;95:1548–1551.
OffitKSagiMHurleyK. Preimplantation genetic diagnosis for cancer syndromes: a new challenge for preventive medicine. JAMA2006;296:2727–2730.
WarnerEPlewesDBHillKA. Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA2004;292:1317–1325.
KriegeMBrekelmansCTBoetesC. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med2004;351:427–437.
LeachMOBoggisCRDixonAK. Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). Lancet2005;365:1769–1778.
StoutjesdijkMJBoetesCJagerGJ. Magnetic resonance imaging and mammography in women with a hereditary risk of breast cancer. J Natl Cancer Inst2001;93:1095–1102.
KuhlCKSchradingSLeutnerCC. Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer. J Clin Oncol2005;23:8469–8476.
Tilanus-LinthorstMVerhoogLObdeijnIM. A BRCA1/2 mutation, high breast density and prominent pushing margins of a tumor independently contribute to a frequent false-negative mammography. Int J Cancer2002;102:91–95.
EvansDGGaarenstroomKNStirlingD. Screening for familial ovarian cancer: poor survival of BRCA1/2 related cancers. J Med Genet2009;46:593–597.
WoodwardERSleightholmeHVConsidineAM. Annual surveillance by CA125 and transvaginal ultrasound for ovarian cancer in both high-risk and population risk women is ineffective. BJOG2007;114:1500–1509.
HartmannLCSchaidDJWoodsJE. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med1999;340:77–84.
HartmannLCSellersTASchaidDJ. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst2001;93:1633–1637.
Meijers-HeijboerHvan GeelBvan PuttenWL. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med2001;345:159–164.
RebbeckTRFriebelTLynchHT. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol2004;22:1055–1062.
van DijkSvan RoosmalenMSOttenWStalmeierPF. Decision making regarding prophylactic mastectomy: stability of preferences and the impact of anticipated feelings of regret. J Clin Oncol2008;26:2358–2363.
LevineDAArgentaPAYeeCJ. Fallopian tube and primary peritoneal carcinomas associated with BRCA mutations. J Clin Oncol2003;21:4222–4227.
PiverMSJishiMFTsukadaYNavaG. Primary peritoneal carcinoma after prophylactic oophorectomy in women with a family history of ovarian cancer. A report of the Gilda Radner Familial Ovarian Cancer Registry. Cancer1993;71:2751–2755.
Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Anglian Breast Cancer Study Group. Br J Cancer2000;83:1301–1308.
SatagopanJMBoydJKauffND. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. Clin Cancer Res2002;8:3776–3781.
RebbeckTRKauffNDDomchekSM. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst2009;101:80–87.
FinchAShawPRosenB. Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers. Gynecol Oncol2006;100:58–64.
KauffNDSatagopanJMRobsonME. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med2002;346:1609–1615.
KemelYKauffNDRobsonME. Four-year follow-up of outcomes following risk-reducing salpingo-oophorectomy in BRCA mutation carriers [abstract]. J Clin Oncol2005;23(Suppl 1):Abstract 1013.
RebbeckTRLevinAMEisenA. Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst1999;91:1475–1479.
EisenALubinskiJKlijnJ. Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study. J Clin Oncol2005;23:7491–7496.
KauffNDDomchekSMFriebelTM. Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. J Clin Oncol2008;26:1331–1337.
PowellCBKenleyEChenLM. Risk-reducing salpingo-oophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy. J Clin Oncol2005;23:127–132.
RebbeckTRFriebelTWagnerT. Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol2005;23:7804–7810.
EisenALubinskiJGronwaldJ. Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers. J Natl Cancer Inst2008;100:1361–1367.
ChlebowskiRTPrenticeRL. Menopausal hormone therapy in BRCA1 mutation carriers: uncertainty and caution. J Natl Cancer Inst2008;100:1341–1343.
GarberJEHartmanAR. Prophylactic oophorectomy and hormone replacement therapy: protection at what price?J Clin Oncol2004;22:978–980.
KingMCWieandSHaleK. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. JAMA2001;286:2251–2256.
McLaughlinJRRischHALubinskiJ. Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study. Lancet Oncol2007;8:26–34.
NarodSARischHMoslehiR. Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group. N Engl J Med1998;339:424–428.
HaileRWThomasDCMcGuireV. BRCA1 and BRCA2 mutation carriers, oral contraceptive use, and breast cancer before age 50. Cancer Epidemiol Biomarkers Prev2006;15:1863–1870.
NarodSADubeMPKlijnJ. Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst2002;94:1773–1779.